Reversal and prove-it: Confirmation of the concept "the lower, the better" for cholesterol therapy in patients with coronary heart disease;Reversal et prove-it: Confirmation du concept "the lower, the better" dans le traitement de l'hypercholestérolemie chez le patient coronarien

Revue Medicale de Liege

Volumn 59, Issue 3, 2004, Pages 167-173

  Scheen, A J ^a   Kulbertus, H ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atorvastatin; Coronary heart disease; Evidence based medicine; HMG CoA reductase inhibitor; Hypercholesterolaemia; Pravastatin; Prevention

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS;

EID: 1942499530     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Scheen AJ.-Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
2. Scheen AJ.-Les statines: du récepteur LDL à la protection cardio-vasculaire. Rev Med Liège, 1996, 51, 95-99.
3. Jones P, Kafonek S, Laurora I, Hunninghake D.-Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol, 1998, 81, 582-587.
4. Jones PH, Davidson MH, Stein EA, et al for the STELLAR Study Group.-Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol, 2003, 93, 152-160.
5. Law MR, Wald NJ, Rudnicka AR.-Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
6. Topol EJ.-Intensive statin therapy - A sea change in cardiovascular prevention (Editorial). N Engl J Med, 2004, 350, N° April 8.
7. Scheen AJ, Lefèbvre PJ, Kulbertus H.-Comment je préviens ... Les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une "polypill"? Rev Med Liège, 2003, 57, 527-533.
8. Roberts WC.-The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol, 1996, 78, 377-378.
9. van Wissen S, Trip MD, Smilde TJ, et al.-Differential CRP reduction in patients with famililal hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis, 2002, 165, 361-366.
10. Pitt B, Mancini GB, Ellis SG, et al.-Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol, 1995, 26, 1133-1139.
11. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al.-B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol, 1998, 31, 1561-1567.
12. Davidson MH.-Statin trials in progress: unanswered questions. Curr Atheroscler Rep, 2001, 3, 9-13.
13. Scheen AJ, Kulbertus H.-Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
14. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.-Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1600-1609.
15. Jacobson TA.-"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med, 2000, 133, 549-554.
16. Bonetti PO, Lerman LO, Napoli C, Lerman A.-Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J, 2003, 24, 225-248.
17. Nissen SE, Tuzcu EM, Schoenhagen P, et al.-Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial. JAMA, 2004, 291, 1071-1080.
18. Cannon CP, Braunwald E, McCabe CH, et al.-Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350, N° April 8.
19. Naghavi M, Libby P, Falk E, et al.-From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies, part 1. Circulation, 2003, 108, 1664-1672.
20. Smidle TJ, van Wissen S, Wollersheim H, et al.-Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet, 2001, 357, 577-581.
21. Taylor AJ, Kent SM, Flaherty PJ, et al.-ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation, 2002, 106, 2055-2060.
22. Sacks FM.-High-intensity statin treatment for coronary heart disease (Editorial). JAMA, 2004, 291, 1132-1134.
23. Schwartz GG, Olsson AG, Ezekowitz MD, et al.-Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001, 285, 1711-1718.
24. Scheen AJ.-L'étude "MIRACL" ou "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering". Rev Med Liège, 2000, 55, 1064-1066.
25. Arntz H-R, Agrawal R, Wunderlich W, et al.-Beneficial effects of pravastatin (+- colestyramine / niacin) initiated immediately after a coronary event (the randomized lipid coronary artery disease [L-CAD] study). Am J Cardiol, 2000, 86, 1293-1298.
26. Simes J, Furberg CD, Braunwald E, et al.-Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J, 2002, 23, 207-215.
27. Kulbertus H, Scheen AJ.-La MRC/BHF Heart Protection Study. Rev Med Liège, 2002, 57, 613-616.
28. Kulbertus H, Scheen AJ.-L'étude PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Rev Med Liège, 2002, 57, 809-813.
29. LaRosa JC.-New and emerging data from clinical trials of statins. Curr Atheroscler Rep, 2004, 6, 12-19.
30. Scheen AJ.-Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
31. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.-ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 2002, 40, 567-572.